@article {10795, title = {How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease.}, journal = {Expert Rev Gastroenterol Hepatol}, volume = {12}, year = {2018}, month = {2018 Aug}, pages = {797-810}, abstract = {

INTRODUCTION: Anti-tumor necrosis factor (TNF) agents have changed the therapeutic approach to inflammatory bowel disease (IBD). However, a considerable proportion of patients either do not primarily respond or lose response to treatment. Despite the long-standing experience in the use of these drugs, still there is the need of identifying the possible predictors of efficacy. Areas covered: We critically review the current knowledge on predictors of response to anti-TNF therapy - both those available in clinical practice and those still under investigation. Multiple factors are involved in treatment success, including disease phenotype and severity, adherence to medications, and pharmacogenomic, pharmacokinetic, and immunologic factors. Literature search was conducted in PubMed using keywords {\textquoteright}inflammatory bowel disease,{\textquoteright} {\textquoteright}Crohn{\textquoteright}s disease,{\textquoteright} and {\textquoteright}ulcerative colitis,{\textquoteright} matched with {\textquoteright}antitumor necrosis factor,{\textquoteright} {\textquoteright}biologic therapy,{\textquoteright} {\textquoteright}clinical response,{\textquoteright} {\textquoteright}predictors,{\textquoteright} and {\textquoteright}efficacy,{\textquoteright} Relevant articles were selected for review. Expert commentary: While the role of several factors in clinical practice is clearly established, other investigational markers have been proposed, mostly in small studies, yet for many of them little external validation exists. Therapeutic drug monitoring is emerging as a pivotal strategy to guide decisions in clinical practice. In the near future, novel markers could improve our ability to direct treatment and personalize therapy.

}, keywords = {Antibodies, Monoclonal, Biological Therapy, Gastrointestinal Agents, Humans, Inflammatory Bowel Diseases, Patient Selection, Prognosis, Treatment Outcome, Tumor Necrosis Factor-alpha}, issn = {1747-4132}, doi = {10.1080/17474124.2018.1494573}, author = {Naviglio, Samuele and Giuffrida, Paolo and Stocco, Gabriele and Lenti, Marco Vincenzo and Ventura, Alessandro and Corazza, Gino Roberto and Di Sabatino, Antonio} } @article {8346, title = {Innate and adaptive immunity in self-reported nonceliac gluten sensitivity versus celiac disease.}, journal = {Dig Liver Dis}, volume = {48}, year = {2016}, month = {2016 Jul}, pages = {745-52}, abstract = {

BACKGROUND: Immune mechanisms have been implicated in nonceliac gluten sensitivity (NCGS), a condition characterized by intestinal and/or extraintestinal symptoms caused by the ingestion of gluten in non-celiac/non-wheat allergic individuals.

AIMS: We investigated innate and adaptive immunity in self-reported NCGS versus celiac disease (CD).

METHODS: In the supernatants of ex vivo-cultured duodenal biopsies from 14 self-reported NCGS patients, 9 untreated and 10 treated CD patients, and 12 controls we detected innate cytokines - interleukin (IL)-15, tumor necrosis factor-α, IL-1β, IL-6, IL-12p70, IL-23, IL-27, IL-32α, thymic stromal lymphopoietin (TSLP), IFN-α-, adaptive cytokines - interferon (IFN)-γ, IL-17A, IL-4, IL-5, IL-10, IL-13-, chemokines - IL-8, CCL1, CCL2, CCL3, CCL4, CCL5, CXCL1, CXCL10-, granulocyte colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF).

RESULTS: Mucosal innate and adaptive cytokines, chemokines and growth factors did not differ between self-reported NCGS, treated CD and controls. On the contrary, IL-6, IL-15, IL-27, IFN-α, IFN-γ, IL-17A, IL-23, G-CSF, GM-CSF, IL-8, CCL1 and CCL4 were significantly higher in untreated CD than in self-reported NCGS, treated CD and controls, while TSLP was significantly lower in untreated CD than in self-reported NCGS, treated CD and controls.

CONCLUSION: In our hands, patients with self-reported NCGS showed no abnormalities of the mucosal immune response.

}, issn = {1878-3562}, doi = {10.1016/j.dld.2016.03.024}, author = {Di Sabatino, Antonio and Giuffrida, Paolo and Fornasa, Giulia and Salvatore, Chiara and Vanoli, Alessandro and Naviglio, Samuele and De Leo, Luigina and Pasini, Alessandra and De Amici, Mara and Alvisi, Costanza and Not, Tarcisio and Rescigno, Maria and Corazza, Gino Roberto} }